Resmed Inc’s recently made public that its Officer Rider Michael J acquired Company’s shares for reported $9995.0 on Jun 02 ’25. In the deal valued at $243.78 per share,41 shares were bought.
Then, Sandercock Brett bought 1,000 shares, generating $243,780 in total proceeds.
Before that, Sandercock Brett sold 3,644 shares. Resmed Inc shares valued at $891,286 were divested by the Chief Financial Officer at a price of $244.59 per share. As a result of the transaction, Sandercock Brett now holds 86,283 shares, worth roughly $21.06 million.
Morgan Stanley initiated its Resmed Inc [RMD] rating to an Overweight in a research note published on March 19, 2025; the price target was $280. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Goldman began covering RMD with “Buy” recommendation on January 16, 2025. Piper Sandler started covering the stock on January 10, 2025. It rated RMD as “a Neutral”.
Price Performance Review of RMD
On Monday, Resmed Inc [NYSE:RMD] saw its stock fall -0.31% to $244.03. Over the last five days, the stock has gained 0.49%. Resmed Inc shares have risen nearly 6.71% since the year began. Nevertheless, the stocks have risen 18.48% over the past one year. While a 52-week high of $263.05 was reached on 01/30/25, a 52-week low of $179.42 was recorded on 04/07/25. SMA at 50 days reached $230.84, while 200 days put it at $236.67.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 241.17, which if violated will result in even more drops to 238.31. On the upside, there is a resistance level at 245.65. A further resistance level may holdings at 247.28. The Relative Strength Index (RSI) on the 14-day chart is 55.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 69.66%. Stochastics %K at 26.55% indicates the stock is a holding.
The most recent change occurred on December 13, 2024 when Stifel began covering the stock and recommended ‘”a Hold”‘ rating along with a $250 price target.
